Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of...

Area of Science:

• Bioinformatics
• Computational Biology
• Genomics

Background:

• Precision medicine relies on molecular signatures from omics data for clinical decisions.
• Current omics signature approaches are often platform-specific, limiting their real-world application and transferability.
• Technical variations across platforms and centers introduce noise, hindering consistent molecular signature performance.

Purpose of the Study:

• To develop a novel computational model for platform-independent prediction of patient outcomes using omics data.
• To enhance the transferability and stability of molecular signatures across different experimental conditions and datasets.
• To establish a robust framework for clinical screening in precision medicine.

Main Methods:

• Introduced Cross-Platform Omics Prediction (CPOP), a penalized regression model.
• Utilized ratio-based features with similar estimated effect sizes instead of gene-based features.
• Evaluated CPOP's performance on melanoma, ovarian cancer, and inflammatory bowel disease omics datasets.

Main Results:

• CPOP demonstrated stable performance across diverse datasets by minimizing technical noise.
• The model achieved platform-independent prediction of patient outcomes, enhancing signature transferability.
• Successful validation was shown across multiple cancer types and an inflammatory disease study.

Conclusions:

• CPOP offers a robust solution for platform-independent molecular signature analysis in precision medicine.
• The model's ability to generalize across datasets and platforms facilitates broader clinical utility.
• CPOP represents a significant advancement in leveraging omics data for reliable patient outcome prediction.